The organisation Women’s Cannabis Project has developed a new European policy framework for medical cannabis in women’s health conditions. The framework is part of a broader movement for what advocates call gender-informed cannabis policy.
The background is a series of US state decisions. In January 2025, Illinois approved four women-specific conditions for treatment with medical cannabis: endometriosis, ovarian cysts, uterine fibroids and female orgasmic disorder (FOD). FOD has also been approved in Connecticut and is under review in Oregon.
Kelsey Engvik, director of the Women’s Cannabis Project, describes the work as a shift from advocacy to results. The European advisory council is chaired by Eliane Eggler.
It is worth keeping the categories apart. This concerns medical cannabis, which is prescription-only, regulated as a medicine and may contain high levels of THC. That is something other than industrial hemp (under 0.3% THC) and CBD products sold as ordinary consumer goods within the EU. The news says nothing about what such products do or do not do.
According to Cannabis Health News, the framework was to be presented by Eliane Eggler at an industry conference in Zurich later in May 2026.